IBI-319

N/A

Report date: 2022/01/21 14:25:10

Base Information

Drug NameIBI-319
Drug Alias NameIBI-319
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionImmunomodulatorsProgrammed cell death protein 1 blockersTumor necrosis factor receptor superfamily member 9 agonists
TargetsProgrammed cell death protein 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEli Lilly And CompanyInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A